A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358

被引：0
|
作者：
Spear, M. A.
LoRusso, P.
Tolcher, A. W.
Lin, C.
Wang, D.
Heath, E.
Lloyd, G. K.
Cropp, G.
Papadopoulos, K. P.
机构：
[1] Nereus Pharmaceut, San Diego, CA USA
[2] Karmanos Canc Ctr, Detroit, MI USA
[3] Inst Drug Dev, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14097
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent
    Boocock, David J.
    Faust, Guy E. S.
    Patel, Ketan R.
    Schinas, Anna M.
    Brown, Victoria A.
    Ducharme, Murray P.
    Booth, Tristan D.
    Crowell, James A.
    Perloff, Marjorie
    Gescher, Andreas J.
    Steward, William P.
    Brenner, Dean E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (06) : 1246 - 1252
  • [42] Phase 1 Dose Escalation Study of Accelerated Fractionation and Concurrent Chemotherapy Using Intensity Modulated Radiation Therapy for Locally Advanced Lung Cancer
    Kelsey, C. R.
    Marks, L. B.
    Das, S.
    Dunphy, F.
    Ready, N.
    Crawford, J.
    Yoo, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S213 - S214
  • [43] Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
    Oh, Do-Youn
    Kim, Tae-Min
    Han, Sae-Won
    Shin, Dong-Yeop
    Lee, Yun Gyoo
    Lee, Keun-Wook
    Kim, Jee Hyun
    Kim, Tae-You
    Jang, In-Jin
    Lee, Jong-Seok
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 28 - 36
  • [44] An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
    H. Murakami
    T. Kurata
    Y. Onozawa
    J. Watanabe
    A. Ono
    T. Takahashi
    N. Yamamoto
    Y. Fujisaka
    H. Kiyota
    H. Hayashi
    K. Tanaka
    K. Nakagawa
    S. Kuroda
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 623 - 630
  • [45] An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
    Murakami, H.
    Kurata, T.
    Onozawa, Y.
    Watanabe, J.
    Ono, A.
    Takahashi, T.
    Yamamoto, N.
    Fujisaka, Y.
    Kiyota, H.
    Hayashi, H.
    Tanaka, K.
    Nakagawa, K.
    Kuroda, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 623 - 630
  • [46] A dose escalation phase 1 study of radiotherapy combined with ipilimumab in metastatic melanoma.
    Boutros, C.
    Chaput, N.
    Lanoy, E.
    Larive, A.
    Mateus, C.
    Routier, E.
    Roy, S.
    Sun, R.
    Lancia, A.
    Tao, Y. G.
    Ibrahim, N.
    Khoury-Abboud, R.
    Massard, C.
    Bahleda, R.
    Schwob, D.
    Caramella, C.
    Cassard, L.
    Soria, J.
    Robert, C.
    Deutsch, E.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S646 - S647
  • [47] Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1)
    Mariangela Massaccesi
    Marica Ferro
    Savino Cilla
    Mario Balducci
    Francesco Deodato
    Gabriella Macchia
    Vincenzo Valentini
    Alessio G. Morganti
    International Journal of Clinical Oncology, 2013, 18 : 784 - 791
  • [48] Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1)
    Massaccesi, Mariangela
    Ferro, Marica
    Cilla, Savino
    Balducci, Mario
    Deodato, Francesco
    Macchia, Gabriella
    Valentini, Vincenzo
    Morganti, Alessio G.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (05) : 784 - 791
  • [49] A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
    Eskens, F. A. L. M.
    Tresca, P.
    Tosi, D.
    Van Doorn, L.
    Fontaine, H.
    Van der Gaast, A.
    Veyrat-Follet, C.
    Oprea, C.
    Hospitel, M.
    Dieras, V.
    BRITISH JOURNAL OF CANCER, 2014, 110 (09) : 2170 - 2177
  • [50] A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
    F A L M Eskens
    P Tresca
    D Tosi
    L Van Doorn
    H Fontaine
    A Van der Gaast
    C Veyrat-Follet
    C Oprea
    M Hospitel
    V Dieras
    British Journal of Cancer, 2014, 110 : 2170 - 2177
12345